Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience.
Head Neck
; 45(5): 1071-1079, 2023 05.
Article
de En
| MEDLINE
| ID: mdl-36840929
ABSTRACT
BACKGROUND:
Recurrent respiratory papillomatosis (RRP) is a currently incurable benign neoplasm caused by human papilloma virus (HPV) infection. It usually reduces voice, respiratory, and general quality of life, and is sometimes life-threatening. Patients usually need repeated operations. The use of adjuvant bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A, has been described in several case reports, with a good efficacy and safety profile.METHODS:
We report the cases of five patients with aggressive RRP who were treated with adjuvant systemic bevacizumab in a single Belgian tertiary center.RESULTS:
A complete response was achieved in four patients after a median of 4.5 months, and a partial response in one. In all cases, the number of surgeries was drastically reduced, and quality of life improved. Toxicity was easily managed.CONCLUSIONS:
Systemic bevacizumab seems to be an effective and safe adjuvant treatment for aggressive RRP.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Infections de l'appareil respiratoire
/
Infections à papillomavirus
Aspects:
Patient_preference
Limites:
Humans
Pays/Région comme sujet:
Europa
Langue:
En
Journal:
Head Neck
Sujet du journal:
NEOPLASIAS
Année:
2023
Type de document:
Article
Pays d'affiliation:
Belgique